secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001171843-23-004975
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos reports Q2 net loss $18.8M; cash $90.8M; NASH program on track for Q4 Phase 2a filing
--------------------------------------------------------------------------------

- Net loss $18.8M ($0.43/shr) vs $19.9M ($0.47) in Q2 2022.
- Cash $90.8M at June 30, 2023, down from $125.8M; sufficient through end 2024.
- NASH candidate ALG-055009 Phase 1 complete; Phase 2a protocol filing expected Q4 2023; topline data Q4 2024.
- COVID-19 protease inhibitor ALG-097558: first-in-human dosing ongoing; topline data H1 2024.
- Agreement in principle with Janssen to resolve litigation; case stayed July 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184323004975/0001171843-23-004975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184323004975/f8k_080323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer